Selective potentiations in opioid analgesia following scopolamine pretreatment.
The effects of the muscarinic receptor antagonist scopolamine upon analgesia induced by D-ala-D-leu-enkephalin (DADL), beta-endorphin (BEND) and morphine were examined. While scopolamine (10 mg/kg, IP) significantly potentiated the analgesic responses following DADL (40 micrograms, ICV) and morphine (5 mg/kg, SC) on the jump test, it failed to alter significantly BEND (1 microgram, ICV) analgesia.
D000818:Animals; D004357:Drug Synergism; D004723:Endorphins / Q000494:pharmacology*; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D016308:Enkephalin, Leucine-2-Alanine; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012601:Scopolamine / Q000494:pharmacology*; D001615:beta-Endorphin
D004723:Endorphins; D004743:Enkephalin, Leucine; D001615:beta-Endorphin; D016308:Enkephalin, Leucine-2-Alanine; D009020:Morphine; D012601:Scopolamine